BGIM
ATNM icon

Brandywine Global Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Brandywine Global Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-89,700
Closed -$169K – 569
2024
Q3 		$169K Sell
89,700
-38,500
-30% -$152K ﹤0.01% 651
2024
Q2 		$949K Sell
128,200
-17,400
-12% -$143K 0.01% 632
2024
Q1 		$1.14M Hold
145,600
– – 0.01% 626
2023
Q4 		$740K Sell
145,600
-28,900
-17% -$149K 0.01% 654
2023
Q3 		$1.03M Buy
+174,500
New +$1.16M 0.01% 629

Other funds holding ATNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $27.2B AUM 43.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Brandywine Global Investment Management's ATNM Position: Q4 2024 in Review

Brandywine Global Investment Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 89,700 shares — an estimated $169K sold.

Brandywine Global Investment Management first reported a position in ATNM in Q3 2023 and held it in 5 quarters. The position peaked at $1.14M in Q1 2024. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

  • Brandywine Global Investment Management reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Brandywine Global Investment Management sold 89,700 Actinium Pharmaceuticals shares in Q4 2024, an estimated $169K.
  • Brandywine Global Investment Management first reported a position in Actinium Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Brandywine Global Investment Management's Actinium Pharmaceuticals position peaked at $1.14M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Brandywine Global Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.